JOHN B III HENNEMAN
CIK 1187572 · Chief Administrative Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.47M
Companies
7
Total Filings
131
Lifetime Open-Market Net
-$21.31M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANIK | Director | 65,273 | $16.11 | $1.05M | $159.0K | 9 | 2026-06-23 |
| APRE | Director | 13,364 | $0.64 | $8.6K | $125.0K | 9 | 2026-06-17 |
| OFIX | Director | 105,774 | $12.13 | $1.28M | $61.3K | 6 | 2026-06-12 |
| R1 RCM Inc. /DE (RCM) Delisted | Director | 0 | $14.31 | $0 | -$858.6K | 30 | 2024-11-19 |
| SeaSpine Holdings Corp (SPNE) Delisted | Director | 82,654 | $9.54 | $788.5K | -$296.8K | 12 | 2022-06-03 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Chief Administrative Officer | 6,117 | — | — | $277.4K | 13 | 2018-10-02 |
| IART | CorpVP, CAO | 68,318 | $16.49 | $1.13M | -$20.77M | 43 | 2014-08-26 |
Recent Filings · Page 8 of 14
131 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-01-05 | LUMOS PHARMA, INC. (NLNK) Delisted | Mixed | −1,487 | -$16.3K | EDGAR |
| 2017-01-04 | — | Grant (A) | — | $0 | |
| 2016-10-05 | — | Grant (A) | — | $0 | |
| 2016-10-04 | LUMOS PHARMA, INC. (NLNK) Delisted | Tax (F) | −2,789 | -$41.9K | EDGAR |
| 2016-08-17 | — | Buy (P) | +50,000 | $90.1K | |
| 2016-08-11 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-06 | — | Grant (A) | — | $0 | |
| 2016-06-09 | SeaSpine Holdings Corp (SPNE) Delisted | Grant (A) | +10,010 | $0 | EDGAR |
| 2016-04-05 | — | Grant (A) | — | $0 | |
| 2016-02-24 | — | Grant (A) | — | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.